Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma.
Philip
P
Campbell
Adam
A
Friebe
Paul
P
Foulstone
Andrew
A
Grigg
Jennifer
J
Hempton
Ashish
A
Bajel
D000328:Adult; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000008:administration & dosage / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology / Q000517:prevention & control*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
D051523:Fibroblast Growth Factor 7; D002066:Busulfan; D008558:Melphalan